Steven Schwartz

Dr. Steven Schwartz


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in The Lancet
Verified
Journal Article
Closed access
SSSteven Schwartz
Steven Schwartz
CRCarl D Regillo
Carl D Regillo
BLByron L Lam
Byron L Lam
DEDean Eliott
Dean Eliott
PRPhilip J Rosenfeld
Philip J Rosenfeld
RLRobert Lanza
Robert Lanza

1 April 2016 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
SSSteven Schwartz
Steven Schwartz
GTGavin Tan
Gavin Tan
HHHamid Hosseini
Hamid Hosseini
ANAaron Nagiel
Aaron Nagiel
Advanced macular degeneration is an important cause of vision loss in the United States with over 2 million people affected by the disease. Despite substantial progress in the development of new therapies for wet AMD, the severe visual impairment associated with geographic atrophy in dry AMD or Stargardt disease remains untreatable. Recently, two phase I/II studies involving 18 patients with these diseases have demonstrated that it is possible to safely implant human embryonic stem cell–derived RPE (hESC-RPE) in an attempt to rescue photoreceptors and visual function. The anatomical and functional results are encouraging, with more than half of treated patients experiencing sustained improvements in visual acuity and demonstrating evidence of possible cellular engraftment. However, any conclusions remain tempered by the relatively short follow-up time, lack of a formal control group, poor initial visual acuity, and small number of patients. Aside from an instance of postoperative infectious endophthalmitis, no adverse events related to the cell therapy, such as hyperproliferation, tumorigenicity, or rejection-related inflammation were noted in this initial cohort of 18 patients. These first-in-human safety studies have opened the door to future studies enrolling patients with less advanced disease, treating other diseases that result in RPE loss, employing shorter immunosuppressive regimens, and using alternative strategies for RPE transplantation such as sheets of cells with or without scaffolding to mimic Bruch's membrane. The ultimate goal of these initial safety studies is to promote continued translation of complex biological therapies into meaningful treatment strategies that may address unmet medical needs.

1 March 2013 in Retina
Verified
Journal Article
Closed access
DGDarin R. Goldman
Darin R. Goldman
JHJean-Pierre Hubschman
Jean-Pierre Hubschman
AAAnthony J. Aldave
Anthony J. Aldave
ACAllen Chiang
Allen Chiang
JHJennifer S. Huang
Jennifer S. Huang
SSSteven Schwartz
Steven Schwartz
Purpose: To describe the incidence, timing, visual significance, and management of posterior segment complications after Boston type I keratoprosthesis implantation. Methods: A retrospective chart review was conducted of all consecutive Boston type I keratoprostheses implanted by a single surgeon at a single institution over a 6-year period. Preoperative demographics, postoperative complications, and postoperative visual acuity outcomes were analyzed. Results: One hundred and ten keratoprostheses were implanted in 98 eyes of 94 patients during the period under review. A minimum of 6-month follow-up was available for 83 eyes, with a mean follow-up of 28.2 months (range 6–84 months, median 23.7 months). The mean time to occurrence of any posterior segment complication was 5.6 months (range 0–42.1 months, median 5.2 months, n = 38). After keratoprosthesis surgery, 63% of all eyes had corrected distance visual acuity of 20/200 or better at last follow-up compared with 10% of eyes preoperatively. Thirty-eight eyes (40.9%) experienced at least 1 postoperative posterior segment complication, the most common of which were retinal detachment (16.9%, 14 of 83), choroidal detachment (16.9%, 14 of 83), and sterile vitritis (14.5%, 12 of 83). Corrected distance visual acuity was worse among eyes that experienced posterior segment complications compared with eyes that did not at multiple postoperative follow-up intervals (statistically significant up to 3 years) and at last follow-up (logarithm of the minimum angle of resolution ± SD = 1.45 ± 0.78 vs. 0.89 ± 0.81, P = 0.003). Conclusion: Posterior segment complications occur in a significant percentage of patients after keratoprosthesis surgery, resulting in a persistent reduction of visual acuity in a significant proportion of the affected eyes (corrected distance visual acuity ≤ 20/400 in 61% with complications vs. 24% without complications at last follow-up). Given this, and the anatomic difficulties associated with management of posterior segment complications after keratoprosthesis implantation, it is of particular importance to prevent posterior segment complications, whenever possible, in keratoprosthesis patients.

18 April 2013 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
CPCarolyn K Pan
Carolyn K Pan
GHGad Heilweil
Gad Heilweil
RLRobert Lanza
Robert Lanza
SSSteven Schwartz
Steven Schwartz
Introduction: Retinal degenerations are typically characterized by loss of highly differentiated cell types within the neurosensory retina, such as photoreceptors, or retinal pigment epithelium (RPE). RPE loss is the final common pathway in a number of degenerations including the leading cause of new blindness in the developed world: age-related macular degeneration (AMD). Areas covered: This paper presents the pathophysiologic case for RPE transplantation with stem cell (SC)-derived tissue, a review of the preclinical data substantiating the hypothesis and the initial clinical trials safety data from early human trials. Expert opinion: Targeting the RPE for transplantation with SC-derived tissue presents a reasonable therapeutic opportunity in a variety of important, otherwise untreatable, blinding conditions. Success of cellular replacement strategies is contingent on finding a viable source of replacement cells, establishing a safe technique for delivery and survival of transplanted cells within the host, restoration of normal retinal architecture and stabilization or improvement of vision.

12 December 2019 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
NKNikisha Kothari
Nikisha Kothari
SPStacy L. Pineles
Stacy L. Pineles
DSDavid Sarraf
David Sarraf
FVFederico Velez
Federico Velez
GHGad Heilweil
Gad Heilweil
ITIrena Tsui
Irena Tsui
Background: Pediatric retinal disorders, although uncommon, can be challenging to assess in the clinic setting and often requires an exam under anesthesia. The purpose of our study was to evaluate the use of ultra-wide field retinal imaging in children without sedation in an outpatient clinic. Methods: We performed a retrospective case series of patients 18 years or younger who received ultra-wide field imaging over a one year period. The age, gender, and clinical course were documented. Color fundus and red-free images were reviewed to assess field of view. Ultra-wide field autofluorescence (UWF-FAF) was evaluated for abnormal autofluorescence patterns and ultra-wide field fluorescein angiography (UWF-FA) was assessed for angiographic phase and field of view. Results: A total of 107 eyes of 55 patients with a mean age of 11.1 years (SD 3.7 years, range 3–18 years) were evaluated. Twenty-seven (49%) patients were male. The most common diagnosis was retinopathy of prematurity (7 of 55 patients, 12.7%) followed by trauma (7.4%), Coats disease (7.4%), and rhegmatogenous retinal detachment (7.4%). The number of quadrants visualized anterior to the equator correlated with patient age (r = 0.4, p < 0.01). On UWF-FA, 6 of 14 patients (43%) had images of the arterial phase captured and 14 of 14 patients (100%) had images of the venous phase or later captured. Conclusions: We demonstrated that UWF imaging is obtainable in children as young as 3 years old without sedation. UWF fundus photography, UWF-FAF and UWF-FA were useful clinical adjuvants to examination and provide additional information for documenting and monitoring pediatric retinal diseases.

6 November 2017 in Vision
Verified
Journal Article
Open access
PDF file
RBRobert Beardsley
Robert Beardsley
SLSimon Law
Simon Law
JCJoseph Caprioli
Joseph Caprioli
ACAnne L. Coleman
Anne L. Coleman
Kouros Nouri-MahdaviKouros Nouri-Mahdavi
Kouros Nouri-Mahdavi
JGJoAnn Giaconi
JoAnn Giaconi
Importance: Traditionally cyclophotocoagulation has been reserved as a treatment of last resort for eyes with advanced stage glaucoma, but increasingly it is offered to eyes with less severe disease. Endoscopic approaches in particular are utilized in increasing numbers of patients despite only a small number of publications on its results. Objective: The purpose of this study was to compare the efficacy and safety of endoscopic and transcleral cyclophotocoagulation (ECP and TCP) procedures in eyes with refractory glaucomas. Design, Setting, and Participants: A chart review was performed on consecutive patients who underwent ECP and TCP at a tertiary ophthalmology care center between January 2000 and December 2010. Cases with fewer than 3 months of follow-up or that had concurrent pressure reducing procedures were excluded. The main outcome measures examined were intraocular pressure (IOP), number of glaucoma medications, best corrected visual acuity (BCVA), additional glaucoma procedure required, and complications. Main Outcomes and Measures: Forty-two eyes (42 patients) that underwent ECP and forty-four eyes (44 patients) that underwent TCP were identified. The TCP group had a statistically higher mean age (71.2 ± 16.7 vs. 58.1 ± 22.9 years, respectively), larger proportion of neovascular glaucoma (40.9% vs. 16.7%), worse initial BCVA (logMAR 2.86 vs. 1.81), and higher preoperative IOP (45.3 vs. 26.6 mmHg) than the ECP group. At 12 months follow-up, the mean IOP difference between groups was not statistically significant, although the change in IOP from baseline to 12 months was greater for the TCP group (p = 0.006). The rates of progression to no light perception (NLP) and phthisis bulbi were significantly higher amongst TCP eyes than ECP eyes (27.2% vs. 4.8%, p = 0.017, and 20.5% vs. 0%, p = 0.003, respectively). Of these eyes that progressed, a majority had neovascular glaucoma (NVG). Corneal decompensation was the most frequent complication following ECP (11.9%). Conclusions and Relevance: In patients with preoperative BCVA of 20/400 or better, overall complication rates (cystoid macular edema, exudative retinal detachment, inflammation, cornea decompensation) were higher after ECP than with TCP. In refractory glaucomas in a real world setting (not a trial), TCP was more frequently used in ischemic eyes. TCP was associated with a higher rate of progression to phthisis bulbi and loss of light perception than ECP. However, ECP was associated with a clinically significant rate of corneal decompensation. These outcomes likely were related to the severity of underlying ocular diseases found in these eyes.